The impact of palivizumab reimbursement criteria on neonatal RSV hospitalizations and drug prescriptions: an area-based cohort study from the Tuscany Region, Italy
More details
Hide details
1
Epidemiology Unit, Meyer Children’s Hospital, Florence, Italy
2
Observatory of Epidemiology, Regional Health Agency of Tuscany, Florence, Italy
3
Medical Specialization School of Hygiene and Preventive Medicine, University of Florence, Italy
4
Neonatal Intensive Care Unit, Meyer Children’s Hospital, Florence, Italy
Publication date: 2023-04-26
Popul. Med. 2023;5(Supplement):A1198
ABSTRACT
Background and Objective:
Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants aged 29 weeks. The study aimed to evaluate the impact of the 2016 restrictions (intervention) on RSV hospitalizations and palivizumab prescriptions for infants aged